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Partial nephrectomy (PN) oﬀers equivalent oncologic outcomes to radical nephrectomy (RN) but has greater preservation of renal
function and less risk of chronic kidney disease and cardiovascular disease. Laparoscopic PN remains underutilized likely because
it is a technically challenging operation with higher rates of perioperative complications compared to open PN and laparoscopic
RN. A review of the latest PN literature demonstrates that recent advancements in laparoscopic approaches, imaging modalities,
ischemic mitigating strategies, renorrhaphy techniques, and hemostatic agents will likely allow greater utilization of LPN and
expand its usage to increasingly more complex tumors.
1.Introduction
Partial Nephrectomy (PN) is the treatment of choice when-
ever feasible for enhancing renal masses [1–3]. For a mul-
titude of reasons, PN has evolved from an operation perfor-
med in patients with an absolute indication for nephron
sparing surgery (NSS) to avoid dialysis (solitary kidney, bi-
lateral synchronous masses, or hereditary syndrome), to the
preferred procedure for patients with renal masses <7cm
even with a normal contralateral kidney [4].
2. Rationale for a Partial Nephrectomy
PN has proven to provide equivalent oncological outcomes
to radical nephrectomy (RN) for renal tumors <4cm(T1a)
and,evenmorerecently,tumors<7cm(T1b)[5–9].Multiple
retrospective studies have shown no diﬀerence between PN
and RN with regard to cancer-speciﬁc survival and rate to
distant metastasis at long-term follow-up, but with greater
renal function perseveration with PN [9–13]. Furthermore,
several retrospective studies associate PN with better overall
survival compared to RN [10, 14–17]. However, further in-
vestigation is still needed as the only prospective randomized
trial comparing PN with RN showed an overall survival
advantage for RN when using a intention-to-treat analysis
[18].
The risk of local recurrence with PN is also very low [19,
20]. Initial concern over recurrence within the tumor bed
and the need for a wide resection margin, which may have
been deterrents for selecting PN, have been shown to be un-
founded as local recurrences after PN are rare and typically
occur in the presence of grossly positive surgical margins
[19–23].Similarly,theriskformultipletumorfociislessthan
6% for T1a tumors [24]. With improved accuracy of both
preoperative and intraoperative imaging techniques the con-
cern of missing satellite tumor lesions in the ipsilateral kid-
ney is unwarranted. Taken together, the lifetime risk of a new
tumor developing in the ipsilateral kidney is less than 5%
[19], similar to the risk for a tumor in the contra-lateral
kidney [25].
Furthermore, evidence continues to support the beneﬁt
of PN with regard to improved long-term renal and car-
diovascular function [16, 26]. Arguments supporting RN
having minimal impact on renal function have largely been
extrapolated from literature on donor nephrectomy patients
who are carefully screened and selected [27, 28]. Therefore,
much of this evidence is not generalizable to the renal cell
carcinoma population, who tend to be older and at greater
risk for chronic kidney disease (CKD) and death [26].2 Advances in Urology
Withtheincreasing utilizationofcross-sectionalimaging
for other reasons, there continues to be a shift toward small-
er tumor size in patients with signiﬁcant medical comorbidi-
ties,includingrenalinsuﬃciency[26,29,30].Infact,roughly
26% of patients presenting with renal masses <4cmalready
have a baseline-estimated glomerular ﬁltration rate (GFR) of
<60mL/min prior to surgery [31]. Examination of nontu-
mor containing parenchyma of RN specimens has shown
that the majority have some degree of renal histopathologic
abnormalities [32]. Therefore, it is not surprising that RN is
a risk factor for the development or worsening of chronic
kidney disease (CKD) [31].
Increasing attention has also been given to the link be-
tween CKD and cardiovascular disease (CVD) [33–35]. As
GFR decreases, the risk for development of CVD increases as
well [35]. Furthermore, the risk of both death and hospital-
ization increases as GFR drops below <60mL/min [35, 36].
RN is a recognized risk factor for the development and pro-
gression to CKD [31], while preservation of nephrons from
PN can mitigate these eﬀects [10, 26, 31, 37, 38]. Further-
more, retrospective studies comparing PN to RN showed a
reduction in CVD-related morbidity and mortality with PN
[16, 17].
Also it is important to realize that suﬃcient renal func-
tion is required for patients to receive many of the systemic
medical therapies available in the event of recurrence [39].
Withcontinuedadvancementsinmedicaltherapies,nephron
sparing with PN may have an even greater advantages over
RN.
3. Rationale for Laparoscopic
Partial Nephrectomy
Laparoscopic PN (LPN) is an acceptable alternative to open
PN (OPN) for the treatment of T1 renal masses when per-
formed by a skilled laparoscopic surgeon [1, 4], advances in
surgical technique and the use of hemostatic agents have ex-
panded the indications for LPN to more complex renal mas-
ses [40].
LPN has equivalent oncologic outcomes to OPN, albeit
with shorter follow-up, but oﬀers the advantages of mini-
mally invasive surgery [41, 42] .S e v e r a ls t u d i e sh a v ed e m o n -
strated shorter length of hospitalization, quicker overall con-
valescence, lower narcotic requirements, improved cosmesis,
and earlier diet resumption when compared to OPN [4, 43,
44]. The typically shorter length of hospital stay may also
outweigh the usually longer surgical time of LPN to lead to
a lower expense with LPN [45]. Although some experienced
surgeons have been able minimize the morbidity of OPN to
achievesimilarconvalescenceofaminimallyinvasivesurgery
[46–48].
Despite the beneﬁts of LPN, it remains a technically cha-
llenging surgical procedure with a higher rate of intraoper-
ative complications and longer warm ischemia time when
compared to OPN [44, 49]. LPN has also been associated
with increased rate of bleeding and urinary leak periopera-
tively[49,50].ThelongerischemictimeofLPNlikelyreﬂects
the diﬃculty of renorrhaphy with laparoscopy. However,
reﬁnementsinsurgicaltechniqueandtechnologicaladvances
willlikelyleadtoareductionincomplicationrates,improved
outcomes, and more widespread adaption of LPN [42].
4.Laparoscopic Approaches
At this time, no good randomized data exists on the optimal
technique for minimally invasive partial nephrectomy. The
choice of approach is likely to be inﬂuenced by the individual
surgeon’s training and comfort level, as much as patient and
tumor characteristics. Many of the minimally invasive tech-
niques described often mimic the steps of an OPN [51].
In general, the “pure” laparoscopic approach is the most
challenging. Although excellent outcomes are possible in
expert hands, the learning curve is steep [52]. A beginner
to LPN likely should perform at least 10–20 small nonhilar
lesions as their initial case experience [53]. At many commu-
nity and regional hospitals the case volume may not be large
enough to allow proﬁciency in LPN. In these situations, the
approach which maximizes the chance for renal preservation
and excellent oncologic control should be used [54]. For
those with less laparoscopic experience, Hand Assisted
Laparoscopy (HAL) may be a better option for LPN, as it has
a quicker learning curve with reported improvements after
only 4 cases [55, 56]. HAL PN also provides the additional
beneﬁt of allowing compression of renal parenchyma by
hand, which can provide hemostasis without the need for
vessel clamping [55]. If LPN is not feasible, most patients are
better served by an OPN rather than a laparoscopic radical
nephrectomy [16].
Among the biggest advances in minimal invasive surgery
is the introduction of robotic assistance laparoscopy. The be-
neﬁts of 3D vision, 540-degree movement, and tremor elimi-
nation have been well described and there is a growing body
of literature on the use of robotic-assistance in PN [57–59].
Robotic assisted laparoscopic PN (RALPN) also has a shorter
learning curve than traditional LPN [57]. Although early
reports have not shown lower complication rates or shorter
ischemic time, with increasing experience this may change
[52]. Some suggest that robotic assistance will allow an ex-
pansion of LPN to more diﬃc u l tt u m o r s ,s u c ha sp o s t e r i o r ,
central, or hilar lesions [20, 60]. However, implementation
and wide spread adoption of RALPN may be limited by the
increased expense of RALPN over traditional LPN and OPN
[61–63]. A recent meta-analysis revealed traditional LPN, at
a mean direct cost of $10,311, more cost-eﬀective than both
RALPN at $11,962 and OPN $11,427 [62]. Future studies
may reveal that improvements in clinical outcomes can
compensate for the high costs of acquisition, maintenance,
and disposable instruments involved with robotics [63]. This
may only be feasible at centers with high robotic surgical
volume [63].
Another recent development in laparoscopic surgery is
the concept of laparoendoscopic single-site surgery (LESS).
AlthoughstillinitsinfancyforPN,successfulcaseshavebeen
reported with LESS [64]. The loss of instrument triangula-
tion makes LESS diﬃcult, but it is feasible in expert hands
[65]. The use of robotic assistance with LESS may helpAdvances in Urology 3
facilitate this technique [65]. However, other than improved
cosmesis, the beneﬁts of LESS over other laparoscopic ap-
proaches are yet to be determined.
Regardless of the laparoscopic approach initially chosen,
if diﬃculty occurs during the operation, it is more appro-
priate to convert to an open or HAL approach if PN is
still feasible, rather than a laparoscopic RN. The long-term
beneﬁts of nephron sparing surgery certainly outweigh the
short-term advantages of minimally invasive approaches.
5.Novel Imaging
A well-known drawback of laparoscopic surgery is the lack
of tactile feedback it provides; this is particularly true with
robotics. Although this is an area of active investigation, cur-
rently, this shortcoming increases the dependence on preop-
erative imaging and intraoperative visual cues [66].
Preoperative modalities using 3D reconstructions of
helical CT scans or MR angiography provide excellent views
of the relationship of the tumor to the collecting system and
renal vasculature [67]. This may help guide the intrarenal
dissectiontomaximizetheamountofparenchymapreserved
while still achieving negative margins [66].
Preoperative imaging also has an emerging role in dia-
gnosing and determining need for therapy. In the current
era, with the increasing proportion of incidentally found re-
nal masses, a downward stage migration and concomitant
increase in benign pathology has been well described [1, 26,
30]. Novel techniques using immunhistochemical or cyto-
genetics may better predict biological aggressiveness, which
may help determine if treatment is even necessary [68]. An
example of a promising investigation is radio-labeled anti-
bodiesagainstcarbonicanhydrase-IXwithpositronemission
tomography which has excellent positive and negative pre-
dictive values for clear cell phenotype [69].
Another imaging modality which has already gained
widespreadacceptanceistheuseofintraoperative2Dlaparo-
scopic ultrasound to delineate tumor, normal parenchyma,
collecting system, and vasculature in an accurate “real-
time”fashion[70].Studieshavesuggestedthatintraoperative
ultrasound reduces time to hilar dissection and alters clamp-
ingapproachduringLPN[71].However,aswithotherforms
of ultrasound, it is limited by its dependence on the per-
formance and interpretation [70].
Another interesting area of current investigation is the
use of augmented reality navigation systems, which fuse the
anatomic detail of preoperative 3D imaging of CT or MRI
with the real-time information of 2D intraoperative ultra-
sound [72]. Augmented reality imaging can allow the syn-
chronous viewing of the real-time ultrasound image with the
corresponding tomogram slice side by side [66].
Similarly, prototypes of predictive surgical navigation
systems are being explored, which have the potential to
guide the dissection trajectory for safe and accurate tumor
excision in PN [66]. Similar to GPS systems in vehicles, pre-
dictive surgical navigational systems use the combination
of preoperative 3D imaging with intraoperative ultrasound
to correlate the tip of surgical instruments to the surgical
target(i.e.,tumor)andmayassistindeterminingthesurgical
anatomy beyond what is directly visible to the surgeon [66].
Acolor-codedzonalnavigationalsystemhasbeendeveloped,
which correlates to the distance from the target [66]. The
surgical target appears red on the screen, while the margin
within 5mm of the target appears yellow, 5–10mm from the
target appears as a zone of green, and distances greater than
10mm from the edge of the target are blue [66]. This tech-
nology is still in its infancy but may have a greater role with
the increasing utilization of RALPN [66].
6. Renal Ischemia
Several studies suggest a strong correlation between ischemic
time and loss of renal function [73, 74]. This has led to the
concept that every minute of ischemia counts [75]. Various
strategiesha v ebeenpursuedinaneﬀorttoreducetheimpact
of ischemia on renal function [73].
Recently, the traditionally held belief that ischemic time
was the most important determinate of ultimate renal func-
tion has been challenged. When factoring in the percent of
normal parenchyma preserved, ischemic time was no longer
an independent risk factor [76]. The authors of that study
believe that ischemic time is likely just a surrogate for the
complexity of resection, as there is strong correlation with
longer ischemic time with less preservation of parenchyma
[76]. The authors also argue that, although ischemic time is
predictive of acute kidney injury, it is not predictive of long-
term renal function after PN [76]. The authors conclude
that the quantity and quality of parenchyma preserved are
much more important than duration of ischemic time [76].
Thus, eﬀorts to minimize ischemia should not jeopardize the
preservation of as much parenchyma as possible, nor should
ischemiatakeprecedenceovercancercontrolsteps.However,
this does not mean that ischemic time should be ignored. It
still remains an important consideration, just not the most
important.
During LPN, renal ischemia is typically achieved by
clamping of the renal vessels with internal bulldog clamps
or exteriorized handheld satinsky clamp [73]. The use of
a vessel loop for as a tourniquet can also obtain vascular
control [77]. Selective clamping of only the renal artery has
been tried [78]; however, high pneumoperitoneum pressure
mayminimizeanybeneﬁtbycompressingtherenalvein[79].
Selective clamping of only the segmental artery that supplies
the area of resection has also been reported [80].
Several strategies have been described to minimize the
durationofischemictimeduringPN.Earlyunclampingafter
tumor resection allows for a bloodless ﬁeld during tumor
resection but minimizes ischemic time during renorrhaphy
[81, 82]. Similarly, several “no clamp” techniques have been
described, initially reserved for exophytic polar lesions;
however, with increasing comfort with LPN, more complex
masses are being resected “oﬀ clamp” [83]. To aid in mini-
mizing blood loss while “oﬀ clamp,” the use of bipolar or
ultrasonic-based sealing devices for tumor excision has been
used with minimal impact on interpreting margin status
[84]. Focal radiofrequency coagulation prior to resection
with the Habib 4 also allows for hemostasis without
clamping, although cautery artifact can negatively impact4 Advances in Urology
examination of the margins [85, 86]. Induced hypotension
has also been used in an eﬀort to limit hemorrhage while re-
secting without clamping [83].
AlthoughmanyhavereportedsuccessinLPNwithoutthe
need for hilar clamping, one study that used “on-demand”
clamping only in the case of excessive bleeding found their
reduced ischemic time to be associated with higher rates of
blood transfusion and the need for conversion to open for
excessive bleeding [87].
Another ischemia minimizing strategy that avoids hilar
clamping is the use of parenchyma compression for selective
ischemia [88]. This technique is particularly good for polar
lesions and exophytic lesions [88]. During HAL PN com-
pression of renal parenchyma near the lesion can be achieved
by the surgeon’s hand [55]. During pure laparoscopic ap-
proaches, a Simon Renal Pole Clamp can be used [88].
The use of renal cooling is another common strategy for
reducing renal functional decline in LPN that has long been
a part of an OPN [89–91]. On retrospective analysis, warm
and cold ischemia have similar functional outcomes, despite
signiﬁcant longer ischemic time with cold [73, 76]. The
longerischemictimeincoldislikelymultifactorial,including
a selection bias for more diﬃcult reconstructions, the cum-
bersomeness of hypothemia, and perhaps less sense of
urgency for the surgeon [73]. Cold ischemia can be achieved
several diﬀerent ways, such as, surface hypothermia by chil-
led solutions into a laparoscopic endocatch bag [92], retro-
grade instillation of cold perfusate [93], or intra-arterial
infusion of cold perfusate [94].
Pharmacologic renoprotective measures have also been
used to reduce the impact of ischemia. Intravenous mannitol
h a sl o n gb e e nu s e da sa no s m o t i cd i u r e t i ca n dp o t e n t i a lf r e e
radicalscavenger[95].Similarly,furosemidehasbeenusedto
promote diuresis after unclamping of the renal vessels [73].
Future therapies might focus on preconditioning the kidney
toactivatehypoxia-induciblefactorsthatmayminimizeisch-
emia injury [96].
7. Hemostasis of Tumor Bed andClosure
of Collecting System
Suturing is the most eﬀective means of hemostasis and pre-
venting urinary leak; however it is challenging and time-
consuming [97, 98]. Several advances in laparoscopy have
been applied to LPN to make suturing more practical. The
utilization of Hem-o-lok clips and Lapra-Ty clips to replace
some of the knots allows for a tight closure with suture that
is eﬃcient and secure [98, 99]. For similar reasons the use of
barbed suture(Quillor V-Loc) is increasing in popularity for
renorrhaphy [97].
The use of hemostatic agents has allowed an expansion
of laparoscopic surgery for increasingly complex resections
and reconstructions [100]. It is diﬃcult to compare results of
studies on hemostatic agents because of the lack of standar-
dization in controls and because of confounding by the use
of multiple agents to achieve hemostasis [100]. Fibrin seal-
ants allow rapid clot formation when applied to a bloodless
surgical ﬁeld and may induce ﬁbroblast migration con-
tributing to a water-tight seal [101, 102]. Gill et al. have
shownanothersealant,Floseal(humanthrombinandbovine
gelatin), to reduce complications and hemorrhagic events
[103]. Flosealalsotends toswellafterapplication, whichmay
provide an additional beneﬁt of mechanical tamponade
[100].
Polyethylene glycol-based sealants and albumin-gluter-
aldehyde-based sealants undergo covalent polymerization,
whichcanreducebleedingandurinaryleaksduringPN[100,
104–106].Albumin-glutaraldehydeadhesiveshaveevenbeen
used alone successfully in “sutureless” PN on select tumors,
leadingtoreducedischemictimeandimprovedparenchymal
preservation [105].
Additionally, the use of mechanical hemostatic materials,
such as oxidized cellulose, provides a mechanical tamponade
and a surface for platelet adhesion [100].
As previously mentioned, many studies use a combina-
tionofhemostaticmethods.ThecombinationofFlosealwith
rolled bolster has been shown to be most eﬀective for deep
resection beds [107].
8.ExpandingFeasible inLaparoscopic
Partial Nephrectomy
Forthereasonspreviouslydescribed, thecurrentAUAguide-
lines recommend that stage 1 renal masses be treated with
PN over RN whenever feasible or advisable as judged by the
treatingsurgeon[3].Clearly,theterm“feasible”issubjective.
Furthermore, studies show that PN remains underutilized
[108–111], which is likely even more true for minimally in-
vasive approaches [112]. As the aforementioned advances in
LPN continue to gain widespread acceptance, it is likely that
more tumors will be treated by LPN in the future. Similarly,
although current literature on LPN largely reﬂects the ex-
perience of skilled laparoscopic surgeons at centers of ex-
cellence, the previously described advances may narrow the
proﬁciency gap to allow LPN to be performed routinely in
community settings.
However, it is clear that greater objectivity is needed in
describing which tumors are “feasible” for nephron sparing
and minimally invasive approaches. Several descriptive sys-
tems, such as RENAL score, PADUA score, and C-index, use
cross-sectional imaging to add an objective component to
the assessment of renal masses [113–115]. The RENAL score
and PADUA are similar as they both involve assigning points
based on various tumor characteristics [113, 114]. The C-
index diﬀers slightly in that it only looks at tumor size and
proximity to the kidney’s center [115]. The various nephro-
metry scores have been shown to correlate with ischemic
time, perioperative complications, and postoperative esti-
mated GFR [116–118] .T h e s es y s t e m sp r o v i d ea no b j e c t i v e
indicator of tumor complexity allowing for more accurate
comparisons of outcomes and practice patterns [119].
9. Conclusion
PN is the standard of treatment for renal tumors due tor the
preservation of long-term renal function compared to RN.
However, PN currently remains underutilized. LPN oﬀers
severalbeneﬁtsoverOPNbutismoretechnicallychallengingAdvances in Urology 5
and associated with a higher rate of perioperative complica-
tions. However, the advances in laparoscopic approaches,
imagingmodalities,ischemicmitigatingstrategies,renorrha-
phy techniques, and hemostatic agents described previously
will likely allow increasingly more complex renal tumors to
be amenable to LPN.
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